Santarus (NASDAQ: SNTS) Caps off Strong Week with Second FDA Approval Print E-mail
Friday, 04 December 2009 19:44

Santarus (NASDAQ: SNTS) capped off a strong week with its second FDA approval announced AH today.

Following approval of Zegerid OTC earlier in the week, the FDA approved the Company's immediate-release omeprazole / sodium bicarbonate / magnesium hydroxide tablets in 40 mg and 20 mg dosage strengths of omeprazole. The NDA for the new prescription tablet product was approved for all indications the company was seeking, including for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease, or GERD. The Agency has not yet approved a trade name for the new product.

Santarus has submitted an NDA supplement requesting approval of a proposed trade name that includes the “ZEGERID” brand name and anticipates that the FDA will complete its review of this NDA supplement within 180 days, at which time the Company plans to launch the product.

Disclosure: No positions




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter